Improving first-line antiretroviral therapy in resource-limited settings

Current Opinion in HIV and AIDS

Volumn 5, Issue 1, 2010, Pages 38-47

  Ford, Nathan ^a   Calmy, Alexandra ^a,b  

^a MÉDECINS SANS FRONTIÈRES   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Affordability; First line antiretroviral therapy; Resource limited settings; Simplicity

Indexed keywords

ABACAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; CYTOCHROME P450 INHIBITOR; DARUNAVIR; DARUNAVIR PLUS RITONAVIR; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ELVITEGRAVIR; EMTRICITABINE; ETRAVIRINE; FOSAMPRENAVIR PLUS RITONAVIR; GS 9350; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RALTEGRAVIR; RIFAMPICIN; RILPIVIRINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SPI 452; STAVUDINE; TENOFOVIR; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZIDOVUDINE;

ANEMIA; ANTIVIRAL THERAPY; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; DEVELOPING COUNTRY; DISEASE SURVEILLANCE; DRUG COST; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG MEGADOSE; DRUG MONITORING; DRUG POTENCY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; EMERGENCY CARE; HEALTH CARE AVAILABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; LACTIC ACIDOSIS; LIPOATROPHY; LIPODYSTROPHY; LOW DRUG DOSE; NEUROPATHY; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PRACTICE GUIDELINE; PREGNANT WOMAN; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; RISK BENEFIT ANALYSIS; SENSORY NEUROPATHY; STRATEGIC PLANNING; UNSPECIFIED SIDE EFFECT; WORLD HEALTH ORGANIZATION;

ANTI-HIV AGENTS; DEVELOPING COUNTRIES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEALTH SERVICES ACCESSIBILITY; HIV INFECTIONS; HIV-1; HUMANS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; PRACTICE GUIDELINES AS TOPIC; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 74349127079     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e3283339b41     Document Type: Review

References (90)

1. Schwartländer B, Grubb I, Perriëns J. The 10-year struggle to provide antiretroviral treatment to people with HIV in the developing world. Lancet 2006; 368:541-546.
2. McNeil D. Selling cheap 'generic' drugs, India's copycats irk industry. New York Times 1 December 2000.
3. Harries AD, Nyangulu DS, Hargreaves NJ, et al. Preventing antiretroviral anarchy in sub-Saharan Africa. Lancet 2001; 358:410-414.
4. Vareldzis B, Hammer S, Vella S, et al. Introducing WHO's 2002 interim antiretroviral therapy guidelines for resource poor settings [abstract #G12705]. In: The XIV International AIDS Conference; Barcelona, Spain; 7-12 July 2002.
5. WHO. Scaling up antiretroviral therapy in resource-limited settings: guidelines for a public health approach. Geneva: World Health Organization; 2003.
6. Chirac P, Laing R. Updating the WHO essential drugs list. Lancet 2001; 357:1134.
7. Jahn A, Floyd S, Crampin AC, et al. Population-level effect of HIV on adult mortality and early evidence of reversal after introduction of antiretroviral therapy in Malawi. Lancet 2008; 371:1603-1611.
8. Renaud-Thé ry F, Nguimfack BD, Vitoria M, et al. Use of antiretroviral therapy in resource-limited countries in 2006: distribution and uptake of first-and second-line regimens. AIDS 2007; 21 (Suppl 4):S89-S95.
9. Boulle A, van Cutsem G, Hilderbrand K, et al. Good outcomes on ART sustained at five years in Khayelitsha in spite of massive scale up [#abstract WEPED211]. In: 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention; Cape Town, South Africa; 19-22 July 2009.
10. Murphy RA, Sunpath H, Kuritzkes DR, et al. Antiretroviral therapy-associated toxicities in the resource-poor world: the challenge of a limited formulary. J Infect Dis 2007; 196 (Suppl 3):S449-S456.
11. De Clercq E. Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. Int J Antimicrob Agents 2009; 334:307-320.
12. Chou L, Harrington M, Huff B, et al. Pipeline report. NewYork: Treatment Action Group; 2009.
13. WHO. Antiretroviral therapy for HIV infections in adults and adolescents: recommendations for a public health approach. Geneva: World Health Organization; 2006.
14. Bangalore S, Kamalakkannan G, Parkar S, Messerli F. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007; 120:713-719.
15. Carr A, Amin J. Efficacy and tolerability of initial antiretroviral therapy: a systematic review. AIDS 2009; 23:343-353.
16. Van Griensven J, De Naeyer L, Mushi T, et al. High prevalence of lipoatrophy among patients on stavudine-containing first-line antiretroviral therapy regimens in Rwanda. Trans R Soc Trop Med Hyg 2007; 101:793-798.
17. Pujari SN, Dravid A, Naik E, et al. Lipodystrophy and dyslipidemia among patients taking first-line, World Health Organization-recommended highly active antiretroviral therapy regimens in Western India. J Acquir Immune Defic Syndr 2005; 39:199-202.
18. Boulle A, Orrel C, Kaplan R, et al., International Epidemiological Databases to evaluate AIDS in Southern Africa collaboration. Substitutions due to antiretroviral toxicity or contraindication in the first 3 years of antiretroviral therapy in a large South African cohort. Antivir Ther 2007; 12:753-760.
19. Reynolds NR, Neidig JL, Wu AW, et al. Balancing disfigurement and fear of disease progression: patient perceptions of HIV body fat redistribution. AIDS Care 2006; 18:663-673.
20. Brinkman K. Stavudine in antiretroviral therapy: is this the end? AIDS 2009; 23:1727-1729.
21. Nguyen A, Calmy A, Schiffer V, et al., Swiss HIV Cohort Study. Lipodystrophy and weight changes: data from the Swiss HIV Cohort Study, 2000-2006. HIV Med 2008; 9:142-150.
22. Hill A, Ruxeungtham K, Hanvanich M, et al. Systematic review of clinical trials evaluating low doses of stavudine as part of antiretroviral treatment. Expert Opin Pharmacother 2008; 8:679-688.
23. World Health Organization. Addendum to 2006 WHO guidelines on 'antiretroviral therapy for HIV infection in adults and adolescents'. New dosage recommendations for stavudine (d4T). http://www.who.int/hiv/art/ARTadult saddendum.pdf.
24. Isaakidis P, Raguenaud ME, Phe T, et al. Evaluation of a systematic substitution of zidovudine for stavudine-based HAART in a program setting in rural Cambodia. J Acquir Immune Defic Syndr 2008; 49:48-54.
25. NAM. Replacing d4T: what can you afford? HIV & AIDS treatment in practice. HATIP #91; 10 September 2007. http.www.aidsmap.com/cms1236753.pdf
26. Cohen R, Lynch S, Bygrave H, et al. Nurse-driven, community-supported HIV/ AIDS care and treatment: 2 year antiretroviral treatment outcomes from a primary care level programme in rural Lesotho [abstract #MOAD102]. In: 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention; Cape Town, South Africa; 19-22 July 2009.
27. Mwango A, Giganti M, Mulenga L, et al. First-line tenofovir ART: Zambia [abstract #142]. In: 16th Conference on Retroviruses and Opportunistic Infections; Montreal, Canada; 8-11 February 2009.
28. Rosen S, Long L, Fox M, Sanne I. Cost and cost-effectiveness of switching from stavudine to tenofovir in first-line antiretroviral regimens in South Africa. J Acquir Immune Defic Syndr 2008; 48:334-344.
29. Ford N, Gray A, Venter F. Tough choices: tenofovir, tenders and treatment. S Afr J HIV Med 2008; 1:8-10.
30. Danel C, Moh R,Minga A, et al., Trivacan ANRS 1269 trial group. CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a randomised trial. Lancet 2006; 367:1981-1999.
31. El-Sadr WM, Lundgren JD, Neaton JD, et al., Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4p count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283-2296.
32. Ford N. Highlights of the International AIDS Society Conference. Lancet Infect Dis 2009; 9:528.
33. Kitahata MM, Gange SJ, Abraham AG, et al., NA-ACCORD Investigators. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 2009; 360:1815-1826.
34. Phillips AN, Gazzard BG, Clumeck N, et al. When should antiretroviral therapy for HIV be started? BMJ 2007; 334:76-78.
35. Wasserfallen JB, Hyjazi A, Cavassini M. Comparison of HIV-infected patients' characteristics, healthcare resources use and cost between native and migrant patients. Int J Public Health 2009; 54:5-10.
36. Walensky RP, Wolf LL, Wood R, et al., CEPAC (Cost-Effectiveness of Preventing AIDS Complications)-International Investigators. When to start antiretroviral therapy in resource-limited settings. Ann Intern Med 2009; 151:157-166.
37. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000; 342:921-929.
38. Castilla J, Del Romero J, Hernando V, et al. Effectiveness of highly active antiretroviral therapy in reducing heterosexual transmission of HIV. J Acquir Immune Defic Syndr 2005; 40:96-101.
39. Garcia PM, Kalish LA, Pitt J, et al. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group. N Engl J Med 1999; 341:394-402.
40. Lima VD, Johnston K, Hogg RS, et al. Expanded access to highly active antiretroviral therapy: a powerful strategy to curb the HIV epidemic. J Infect Dis 2008; 198:59-67.
41. Granich RM, Gilks CF, Dye C, et al. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 2009; 373:48-57.
42. Kasirye R, Levin J, Munderi P, et al. Epidemiology of malaria in HIV infected Ugandan patients on antiretroviral therapy (ART): a prospective cohort study [abstract #TUPDB104]. In: 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention; Cape Town, South Africa; 19-22 July 2009.
43. Middelkoop K, Wood R, Myer L, et al. Widespread ART is associated with decline in TB prevalence [abstract #WELBB105]. In: 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention; Cape Town, South Africa; 19-22 July 2009.
44. Braitstein P, Boulle A, Nash D, et al., Antiretroviral Therapy in Lower Income Countries (ART-LINC) study group. Gender and the use of antiretroviral treatment in resource-constrained settings: findings from a multicenter collaboration. J Womens Health (Larchmt) 2008; 17:47-55.
45. Madruga JV, Berger D, McMurchie M, et al., TITAN study group. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial. Lancet 2007; 370:49-58.
46. Clotet B, Bellos N, Molina JM, et al., POWER 1 and 2 study groups. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 2007; 369:1169-1178.
47. Ortiz R, Dejesus E, Khanlou H, et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS 2008; 22:1389-1397.
48. Mills AM, Nelson M, Jayaweera D, et al. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive HIV-1-infected patients: 96-week analysis. AIDS 2009; 23:1679-1688.
49. Arribas J, Horban A, Gerstoft J, et al. The MONET trial: darunavir/ritonavir monotherapy shows noninferior efficacy to standard HAART, for patients with HIV RNA <50 copies/mL at baseline [abstract #TUAB106-LB]. In 5th IAS Conference on HIV Pathogenesis Treatment and Prevention; Cape Town, South Africa; 19-22 July 2009.
50. Katlama C, Valentin M, Algarte-Genin M, et al. Efficacy of darunavir/ritonavir as single-drug maintenance therapy in patients with HIV-1 viral suppression: a randomized open-label noninferiority trial, MONOI-ANRS 136 [abstract #WELBB102]. In: 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention; Cape Town, South Africa; 19-22 July 2009.
51. Riddler SA, Haubrich R, DiRienzo AG, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008; 358:2095-2106.
52. French National Agency for Research on AIDS and Viral Hepatitis. Evaluation of 4 new simplified antiretroviral treatments in naive HIV-1 infected patients in Africa (ANRS 12115 DAYANA). Clinical Trials Identifier: NCT00573001.
53. Hirschel B, Calmy A. Initial treatment for HIV infection: an embarrassment of riches. N Engl J Med 2008; 358:2170-2172.
54. Adlington R, Richens J, Shamanesh M. First line therapy in resource-limited settings: time to reconsider? J Infect Dis 2009; 199:1407.
55. Pozniak A. Tenofovir: what have over 1 million years of patient experience taught us? Int J Clin Pract 2008; 62:1285-1293.
56. Winston A, Amin J, Mallon P, et al. Minor changes in calculated creatinine clearance and anion-gap are associated with tenofovir disoproxil fumaratecontaining highly active antiretroviral therapy. HIV Med 2006; 7:105-111.
57. Gallant JE, Parish MA, Keruly JC, Moore RD. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis 2005; 40:1194-1198.
58. Nelson MR, Katlama C, Montaner JS, et al. The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS 2007; 21:1273-1281.
59. Reid A, Stohr W, Walker A, et al. Glomerular dysfunction and associated risk factors through four years following initiation of ART in adults with HIV infection in Africa in the DART trial [abstract #TUPEB184]. In: 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention; Cape Town, South Africa; 19-22 July 2009.
60. Gallant JE, Moore RD. Renal function with use of a tenofovir-containing initial antiretroviral regimen. AIDS 2009; 23:1971-1975.
61. Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 2006; 20:2165-2174.
62. Gallant JE, Staszewski S, Pozniak AL, et al., 903 Study Group. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviralnaive patients: a 3-year randomized trial. JAMA 2004; 292:191-201.
63. CalmyA, Fux CA,NorrisR, et al.Lowbone mineral density, renal dysfunction and fracture risk in HIV infection: a cross-sectional study. J Infect Dis (in press).
64. Parienti JJ, Bangsberg DR, Verdon R, Gardner EM. Better adherence with once-daily antiretroviral regimens: a meta-analysis. Clin Infect Dis 2009; 48: 484-488.
65. Markowitz M, Nguyen BY, Gotuzzo E, et al., Protocol 004 Part II Study Team. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr 2007; 46:125-133.
66. Steigbigel RT, Cooper DA, Kumar PN, et al., BENCHMRK Study Teams. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008; 359:339-354.
67. Lennox JL, DeJesus E, Lazzarin A, et al., for the STARTMRK investigators. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, doubleblind randomised controlled trial. Lancet 2009; 374:796-806.
68. Eron J, Andrade J, Zajdenverg R, et al. Switching from stable lopinavir/ ritonavir-based to raltegravir-based combination ART resulted in a superior lipid profile at week 12 but did not demonstrate non-inferior virologic efficacy at week 24 [abstract #70aLB]. In: 16th Conference on Retroviruses and Opportunistic Infections, Montreal, Canada; 8-11 February 2009.
69. Emory S, Winston A. Raltegravir: a new choice in HIV and new chances for research. Lancet 2009; 374:764-766.
70. Katlama C, Murphy R. Emerging role of integrase inhibitors in the management of treatment-experienced patients with HIV infection. Ther Clin Risk Manag 2009; 5:331-340.
71. Lalezari J, DeJesus E, Osiyemi O, et al. Pharmacokinetics (PK) of once-daily etravirine (ETR) without and with once-daily darunavir/ritonavir (DRV/r) in antiretroviral-naïve HIV-1 infected adults [abstract #O413]. In: 9th International Congress on Drug Therapy in HIV Infection; Glasgow, Scotland; 9-13 November 2008.
72. Garvey L, Winston A. Rilpivirine: a novel nonnucleoside reverse transcriptase inhibitor. Expert Opin Investig Drugs 2009; 18:1035-1041.
73. Crauwels HM, van Heeswijk RPG, Kestens D, Stevens M. The pharmacokinetic interaction between rifabutin and TMC278, an investigational NNRTI [abstract #TUPE0080]. In: XVIIth International AIDS Conference; Mexico City, Mexico, 3-8 August 2008.
74. t'Hoen E. The global politics of pharmaceutical monopoly power. AMB Diemen, Amsterdam 2009. p. 136.
75. Ford N, Wilson D, Costa Chaves G, et al. Sustaining access to antiretroviral therapy in developing countries: lessons from Brazil and Thailand. AIDS 2007; 21:S21-S29.
76. Political activism needed for patent pools for HIV drugs. Lancet 2009; 374:266.
77. World Health Organization. Treat train retain. Task shifting: global recommendations and guidelines. Geneva: WHO; 2007.
78. Van Rie A, Mbonze N, Tillerson K, et al. A nurse-centered primary healthcare model for HIV care of patients with active tuberculosis: antiretroviral treatment initiation decision-making [abstract #TUPED133]. In: 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention; Cape Town, South Africa; 19-22 July 2009.
79. Wood R, Fox M, Cornell M, et al. Nurse management is not inferior to doctor management of antiretroviral naive HIV infected patients [abstract]. In: 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention; Cape Town, South Africa; 19-22 July 2009.
80. Shulman D, Jobarteh K, Makani E, et al. Task-shifting in the pharmacy: a framework for expanding and strengthening services in rural Malawi [abstract #CDD094]. In: 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention; Cape Town, South Africa; 19-22 July 2009.
81. Manosuthi W, Sungkanuparph S, Tantanathip P, et al., N2R Study Team. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study. Clin Infect Dis 2009; 48:1752-1759.
82. French National Agency for Research on AIDS and Viral Hepatitis. Comparison of nevirapine and efavirenz for the treatment of HIV-TB coinfected patients (ANRS 12146 CARINEMO). Clinical Trials Identifier: NCT00495326.
83. Maartens G, Decloedt E, Cohen K. Effectiveness and safety of antiretrovirals with rifampicin: critical issues for high burden countries. Antivir Ther (in press).
84. Dooley KE, Flexner C, Andrade AS. Drug interactions involving combination antiretroviral therapy and other antiinfective agents: repercussions for resource-limited countries. J Infect Dis 2008; 198:948-961.
85. Reynolds S, Bartlett J, Quinn T, et al. Antiretroviral therapy where resources are limited. N Engl J Med 2003; 348:1806-1809.
86. Ford N, Calmy A, von Schoen-Angerer T. Treating HIV in the developing world: getting ahead of the drug development curve. Drug Discov Today 2007; 12:1-3.
87. Caudron JM, Ford N, Henkens M, et al. Substandard medicines in resourcepoor settings: a problem that can no longer be ignored. Trop Med Int Health 2008; 13:1062-1072.
88. Cleary SM, McIntyre D. Affordability: the forgotten criterion in health-care priority setting. Health Econ 2009; 4:373-375.
89. Hogg R, Lima V, Sterne JA, et al. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008; 372:293-299.
90. Keiser O, Orrell C, Egger M, et al., Swiss HIV Cohort Study (SHCS) and the International Epidemiologic Databases to Evaluate AIDS in Southern Africa (IeDEA-SA). Public-health and individual approaches to antiretroviral therapy: township South Africa and Switzerland compared. PLoS Med 2008; 8:e148.